Project Details
| Status | Active |
|---|---|
| Effective start/end date | 24/04/25 → 23/04/30 |
Clinical Trial Phase
- Phase I
- Phase II
- External Sponsor
An open-label, multi-center, phase I/II study of ECI830 as a single agent and in combination with ribociclib and endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors
- Day, Daphne (Chief Investigator (CI))
Project: Research